CXM Financial Facts
Interest expense: -2.11KLoss per common share - basic and diluted: -0.14
See Full Income Statement
Current liabilities: 3.41M
Deficit accumulated during development stage: -114.7M
See Full Balance Sheet
Cardium Therapeutics, Inc. (CXM) Earnings
|
Expand Research on CXM
| Next EPS Date | 12/9/26 | EPS Growth Rate | -8.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +24.4% | Revenue Growth Rate | -1.3% |
| Average % Move 1-Wk after EPS | -3.7% | Normal Earnings Time | N/A |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
12/9/26  |
Q327 | N/A | $0.11 | N/A | N/A | $216.27M | = | N/A | N/A | ||
| 9/2/26 |
Q227 | $0.11 | $0.10 | +$0.01 | $213.7M | $215.56M | = |  | | Details | |
| 6/3/26 | Q127 | $0.11 | $0.10 | +$0.01 | $219.5M | $215.3M | = | | | Details | |
| 3/11/26 | Q426 | $0.13 | $0.09 | +$0.04 | $220.6M | $215.51M | = | | | Details | |
| 12/3/25 | Q326 | $0.12 | $0.09 | +$0.03 | $219.1M | $209.56M | = | | | Details | |
| 9/3/25 |
Q226 | N/A | $0.10 | N/A | N/A | $205.4M | = | N/A | N/A | ||
| 6/4/25 | Q126 | $0.12 | $0.10 | +$0.02 | $205.5M | $201.88M | = | | | Details | |
| 3/12/25 | Q425 | $0.10 | $0.07 | +$0.03 | $202.5M | $200.52M | = | | | Details |
